Close Menu

biomarker discovery

Transcriptome profiles in ovarian cells from young and old non-human primates unearthed expression changes that coincided with flagging fertility in humans.

The multi-omics analytics company is assisting drug discovery and precision medicine as the first partner of Mayo's Clinical Data Analytics Platform.

Hitachi and Centre Léon Bérard have opened a research lab in Lyon that will apply AI to medical imaging and predict response to radiation therapy from genomic markers.

The consortium is comprised of researchers from Inova, Roswell Park Comprehensive Cancer Center, the Mayo Clinic, and MD Anderson Cancer Center.

The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.

The companies plan to explore opportunities to use Thermo Fisher's LC-MS instrumentation to develop tools to determine the risk for adverse pregnancy outcomes.

Tempus is eligible for milestone payments and royalties for any oncology therapeutics Genmab might develop based on their joint research projects.

The German company's new Genome Enhancer product is an adaptation of its flagship multi-omics software for clinicians and biologists without bioinformatics expertise.

The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.

Bioinformaticians at the Free University of Brussels have built a database, machine learning technology, and web platform for identifying elusive pathogenic gene pairs.

Pages

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.